期刊文献+

腹腔内灌注IFN联合PF治疗卵巢癌合并腹水的疗效观察

Combined Introperitoneal Interferon Alpha-2b and Cisplatin Puls 5-FU in Ovarian Cancer Ascites
暂未订购
导出
摘要 目的 :探讨干扰素 (IFN)联合顺铂 (DDP)加 5-氟脲嘧啶 ( 5 FU)腹腔化疗治疗卵巢癌合并腹水的临床疗效。方法 :将 36例卵巢癌合并腹水患者随机分为两组 ,先将腹水尽量放尽。PF组 :腹腔灌注DDP 80mg +5 FU 10 0 0mg +生理盐水 150 0ml ,合并IFN组在PF组基础上加用α 2b IFN 60 0万IU ,两组均每周用药 1次 ,共 3次。治疗 3个疗程后 7~ 14d评定疗效 ,并对两组腹腔化疗后行手术治疗的标本进行病理形态观察。结果 :合并IFN组腹水消退率为 70 % ,肿瘤消退率为 30 % ,均高于PF组 ,差异均有显著性 (分别为P =0 .0 4 2 ;P =0 .0 2 0 ) ;镜检其癌细胞Ⅲ +Ⅳ级反应率明显高于PF组 (P =0 .0 2 8)。结论 :IFN联合PF腹腔化疗治疗卵巢癌合并腹水安全有效 。 Objective:To investigate the effects of the combination introperitoneal interferon alpha 2b(α 2b IFN) and cisplation (DDP) plus 5 FU in ovarian cancer ascites. Methods:36 ovarian cancer ascites were randomized into two groups which drained out ascites as much as possible at first, then received introperitoneal administration once every 1 week altogether three courses.The PF group: DDP 80 mg and 5 FU 1 000 mg which were dissolved in 1 500 ml of natural sodium, the combination IFN group: combination IFN 6×10 6 IU in the base of PF. To evaluate the effects and observation postoperative sample pathology features'changing after three courses.Results: The ascites diminishing rate was 70% and the mass diminishing rate was 30% in the combination IFN group.Both were greater than the PF group.There were significant difference(respectively P=0 042;P=0 020 ).Cancer cells reaction rate in Ⅲ plus Ⅳ grade was greatly increased than PF groud ( P=0 028 ).Conclusion:Combination intraperitoneal IFN and PF in ovarian cancer ascites is effective,safe and promising therapy.
出处 《肿瘤防治杂志》 2000年第5期495-497,共3页 China Journal of Cancer Prevention and Treatment
关键词 干扰素 卵巢肿瘤 腹水 5-FU 治疗 b IFN DDP+5 FU abdominal carity chemotherepy ovarian cancer ascites
  • 相关文献

参考文献6

  • 1[1]Markman M,Reichman B,Hares T,et al.Intraperitoneal chemotherapy in the management of ovarian cancer[J].Cancer,1993,71:1565-1570.
  • 2[2]Greiner JW,Guadagni F,Goldstein D,et al.Intraperitoneal administration of interferon-gamma to carcinoma aptients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells[J].J Clin Oncol,1992,10(5)735-746.
  • 3[3]Bezwoda WR,Golombick T,Dansey R,et al.Treatment of malignant ascites due to recurrent refractory ovarian cancer the use of Interferonalpha or interferon-alpha plus chemotherapy[J ].Eur J Cancer,1991,27:1423-1429.
  • 4[4]Maenpaa J,Kivinen S,Raisanen I.Combined Intraperitoneal interferon alpha-2b and mitoxantrine in refractory ovarian cancer[J].Ann chir Gynaecol Suppl,1992,208:25-27.
  • 5[5]Cherchi PL,Dessole S,Esposito F,et al.Intraperitoneal alpha-2 interferon for advanced orarian cancer in complete remission or minial residual disease[J ].J Gynecol Obstet Biol Reprod (paris),1996,25(1):101-102.
  • 6[6]Berek JS,Charles W,Schink JC,et al.A phase Ⅰ-Ⅱ trial of intraperitoneal cispatin and α-INF in patients with persistent epithelial ovarian cancer[J].Gynecol Oncol,1991,40(3):237-243.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部